Dean J. Naylor
Corporate Officer/Principal bij The University of Queensland
Profiel
Dean J.
Naylor is currently a Principal at The University of Queensland.
Prior to this, he was a Principal at the University of Adelaide and Head-Intellectual Property Development at CBio Ltd.
Actieve functies van Dean J. Naylor
| Bedrijven | Functie | Begin |
|---|---|---|
| The University of Queensland | Corporate Officer/Principal | - |
Eerdere bekende functies van Dean J. Naylor
| Bedrijven | Functie | Einde |
|---|---|---|
| University of Adelaide | Corporate Officer/Principal | - |
CBio Ltd.
 CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
CBio Ltd.
CBio Ltd. BiotechnologyHealth Technology CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia. | Health Technology |
